Lartruvo Dosage
Generic name: olaratumab 10mg in 1mL
Dosage form: injection, solution
Drug class: Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on Sep 16, 2024.
Recommended Dosage
The recommended dose of LARTRUVO is 15 mg/kg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. For the first 8 cycles, LARTRUVO is administered with doxorubicin,.
Refer to doxorubicin prescribing information for dosing, and dose modifications.
Premedication
- Premedicate with diphenhydramine (25 to 50 mg intravenously) and dexamethasone (10 to 20 mg intravenously) prior to LARTRUVO on Day 1 of cycle 1.
Dosing Modifications
Infusion-Related Reactions
- Permanently discontinue LARTRUVO for Grade 3 or 4 infusion-related reactions.
- Interrupt infusion of LARTRUVO for Grade 1 or 2 infusion-related reactions (IRR). After resolution, resume LARTRUVO infusion at 50% of the initial infusion rate.
Neutropenia
- For neutropenic fever/infection or Grade 4 neutropenia lasting longer than 1 week, discontinue administration of LARTRUVO until the absolute neutrophil count is 1,000 /microliter or greater and then permanently reduce the dose to 12 mg/kg.
Preparation and Administration
Preparation
- Inspect vial contents for particulate matter and discoloration prior to dilution. Discard the vial if particulate matter or discolorations are identified.
- Withdraw calculated dose and further dilute with 0.9% Sodium Chloride Injection, USP to a final volume of 250 mL for intravenous infusion. Do not use dextrose-containing or other solutions.
- Gently invert but do not shake.
- DO NOT FREEZE the diluted solution.
- Store the diluted solution for up to 24 hours under refrigeration at 2°C to 8°C (36°F to 46°F) and for up to an additional 8 hours at room temperature (below 25°C [77°F]). Storage times include the duration of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration.
- Discard vial with any unused portion of LARTRUVO.
Administration
- Do not administer LARTRUVO as an intravenous push or bolus. Do not co-infuse with electrolytes or other medications through the same intravenous line.
- Visually inspect the diluted solution for particulate matter and discoloration prior to administration. If particulate matter or discolorations are identified, discard the solution.
- Administer diluted solution as an intravenous infusion over 60 minutes. Flush the line with 0.9% Sodium Chloride Injection, USP at end of infusion.
Frequently asked questions
More about Lartruvo (olaratumab)
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Votrient
Votrient is used to treat renal cell carcinoma (kidney cancer). Learn about side effects ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Yondelis
Yondelis (trabectedin) is used to treat liposarcoma or leiomyosarcoma, two common subtypes of soft ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Tecentriq Hybreza
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous formulation of Tecentriq ...
Atezolizumab/hyaluronidase
Atezolizumab/hyaluronidase is used for alveolar soft part sarcoma, hepatocellular carcinoma ...
Atezolizumab
Atezolizumab (Tecentriq) is a type of immunotherapy drug that helps the body's immune system to ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.